Page last updated: 2024-11-13

vpc32183

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

VPC32183: lysophosphatidic acid (LPA) receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID44392752
CHEMBL ID184055
SCHEMBL ID23014591
MeSH IDM0522729

Synonyms (9)

Synonym
bdbm50150002
phosphoric acid mono-{(r)-2-((z)-octadec-9-enoylamino)-3-[4-(pyridin-3-ylmethoxy)-phenyl]-propyl} ester
(9z)-octadec-9-enamido]-3-[4-(pyridin-3-ylmethoxy)phenyl]propoxy]phosphonic acid
compound 10t [pmid: 15125924]
gtpl2908
vpc32183
CHEMBL184055 ,
SCHEMBL23014591
Q27089158
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Lysophosphatidic acid receptor 1Homo sapiens (human)IC50 (µMol)0.99200.04601.18275.5000AID240871
Lysophosphatidic acid receptor 3Homo sapiens (human)Ki1.68800.03900.43961.6880AID240661
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (35)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayLysophosphatidic acid receptor 1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayLysophosphatidic acid receptor 1Homo sapiens (human)
activation of phospholipase C activityLysophosphatidic acid receptor 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationLysophosphatidic acid receptor 1Homo sapiens (human)
regulation of cell shapeLysophosphatidic acid receptor 1Homo sapiens (human)
negative regulation of neuron projection developmentLysophosphatidic acid receptor 1Homo sapiens (human)
oligodendrocyte developmentLysophosphatidic acid receptor 1Homo sapiens (human)
cerebellum developmentLysophosphatidic acid receptor 1Homo sapiens (human)
optic nerve developmentLysophosphatidic acid receptor 1Homo sapiens (human)
corpus callosum developmentLysophosphatidic acid receptor 1Homo sapiens (human)
bleb assemblyLysophosphatidic acid receptor 1Homo sapiens (human)
positive regulation of Rho protein signal transductionLysophosphatidic acid receptor 1Homo sapiens (human)
myelinationLysophosphatidic acid receptor 1Homo sapiens (human)
positive regulation of apoptotic processLysophosphatidic acid receptor 1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionLysophosphatidic acid receptor 1Homo sapiens (human)
positive regulation of MAPK cascadeLysophosphatidic acid receptor 1Homo sapiens (human)
negative regulation of cAMP-mediated signalingLysophosphatidic acid receptor 1Homo sapiens (human)
positive regulation of stress fiber assemblyLysophosphatidic acid receptor 1Homo sapiens (human)
cell chemotaxisLysophosphatidic acid receptor 1Homo sapiens (human)
positive regulation of dendritic spine developmentLysophosphatidic acid receptor 1Homo sapiens (human)
cellular response to oxygen levelsLysophosphatidic acid receptor 1Homo sapiens (human)
positive regulation of smooth muscle cell chemotaxisLysophosphatidic acid receptor 1Homo sapiens (human)
regulation of synaptic vesicle cycleLysophosphatidic acid receptor 1Homo sapiens (human)
calmodulin dependent kinase signaling pathwayLysophosphatidic acid receptor 1Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationLysophosphatidic acid receptor 1Homo sapiens (human)
negative regulation of cilium assemblyLysophosphatidic acid receptor 1Homo sapiens (human)
cellular response to 1-oleoyl-sn-glycerol 3-phosphateLysophosphatidic acid receptor 1Homo sapiens (human)
neurogenesisLysophosphatidic acid receptor 1Homo sapiens (human)
regulation of metabolic processLysophosphatidic acid receptor 1Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayLysophosphatidic acid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerLysophosphatidic acid receptor 3Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationLysophosphatidic acid receptor 3Homo sapiens (human)
chemical synaptic transmissionLysophosphatidic acid receptor 3Homo sapiens (human)
gene expressionLysophosphatidic acid receptor 3Homo sapiens (human)
bleb assemblyLysophosphatidic acid receptor 3Homo sapiens (human)
positive regulation of MAPK cascadeLysophosphatidic acid receptor 3Homo sapiens (human)
collateral sproutingLysophosphatidic acid receptor 3Homo sapiens (human)
positive regulation of collateral sproutingLysophosphatidic acid receptor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayLysophosphatidic acid receptor 3Homo sapiens (human)
regulation of metabolic processLysophosphatidic acid receptor 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
G-protein alpha-subunit bindingLysophosphatidic acid receptor 1Homo sapiens (human)
G protein-coupled receptor activityLysophosphatidic acid receptor 1Homo sapiens (human)
protein bindingLysophosphatidic acid receptor 1Homo sapiens (human)
PDZ domain bindingLysophosphatidic acid receptor 1Homo sapiens (human)
lysophosphatidic acid bindingLysophosphatidic acid receptor 1Homo sapiens (human)
lysophosphatidic acid receptor activityLysophosphatidic acid receptor 1Homo sapiens (human)
protein bindingLysophosphatidic acid receptor 3Homo sapiens (human)
lipid bindingLysophosphatidic acid receptor 3Homo sapiens (human)
lysophosphatidic acid receptor activityLysophosphatidic acid receptor 3Homo sapiens (human)
G protein-coupled receptor activityLysophosphatidic acid receptor 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
endocytic vesicleLysophosphatidic acid receptor 1Homo sapiens (human)
endosomeLysophosphatidic acid receptor 1Homo sapiens (human)
plasma membraneLysophosphatidic acid receptor 1Homo sapiens (human)
cell surfaceLysophosphatidic acid receptor 1Homo sapiens (human)
presynaptic membraneLysophosphatidic acid receptor 1Homo sapiens (human)
neuronal cell bodyLysophosphatidic acid receptor 1Homo sapiens (human)
dendritic spineLysophosphatidic acid receptor 1Homo sapiens (human)
dendritic shaftLysophosphatidic acid receptor 1Homo sapiens (human)
postsynaptic membraneLysophosphatidic acid receptor 1Homo sapiens (human)
glutamatergic synapseLysophosphatidic acid receptor 1Homo sapiens (human)
GABA-ergic synapseLysophosphatidic acid receptor 1Homo sapiens (human)
cytoplasmLysophosphatidic acid receptor 1Homo sapiens (human)
plasma membraneLysophosphatidic acid receptor 1Homo sapiens (human)
plasma membraneLysophosphatidic acid receptor 3Homo sapiens (human)
axonLysophosphatidic acid receptor 3Homo sapiens (human)
synapseLysophosphatidic acid receptor 3Homo sapiens (human)
plasma membraneLysophosphatidic acid receptor 3Homo sapiens (human)
cytoplasmLysophosphatidic acid receptor 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID240871Inhibitory concentration against Lysophosphatidic acid 1 (LPA1) receptor2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
A novel series of 2-pyridyl-containing compounds as lysophosphatidic acid receptor antagonists: development of a nonhydrolyzable LPA3 receptor-selective antagonist.
AID238308Binding affinity towards Lysophosphatidic acid 1 (LPA1) receptor2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
A novel series of 2-pyridyl-containing compounds as lysophosphatidic acid receptor antagonists: development of a nonhydrolyzable LPA3 receptor-selective antagonist.
AID240661Binding affinity towards Lysophosphatidic acid 3 (LPA3) receptor2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
A novel series of 2-pyridyl-containing compounds as lysophosphatidic acid receptor antagonists: development of a nonhydrolyzable LPA3 receptor-selective antagonist.
AID1346019Mouse LPA1 receptor (Lysophospholipid (LPA) receptors)2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
Initial structure-activity relationships of lysophosphatidic acid receptor antagonists: discovery of a high-affinity LPA1/LPA3 receptor antagonist.
AID1346181Human LPA3 receptor (Lysophospholipid (LPA) receptors)2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
Initial structure-activity relationships of lysophosphatidic acid receptor antagonists: discovery of a high-affinity LPA1/LPA3 receptor antagonist.
AID1346114Human LPA1 receptor (Lysophospholipid (LPA) receptors)2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
Initial structure-activity relationships of lysophosphatidic acid receptor antagonists: discovery of a high-affinity LPA1/LPA3 receptor antagonist.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (54.55)29.6817
2010's5 (45.45)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.72 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (9.09%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]